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  Interleukin (IL)-10 exerts potent anti-inflammatory effects 
by suppression of both T-help (Th) 1 and Th2 cells. Previous 
studies have reported that IL-10 can ameliorate various 
inflammatory disorders. The present study was performed to 
examine  whether  IL-10  plasmid  DNA  could  suppress 
development of atopic dermatitis (AD)-like skin lesions in 
NC/Nga mice, as an initial step towards the development of 
an appliance for use in dogs with AD. Intradermal injection 
of IL-10 plasmid DNA markedly inhibited the development 
of AD-like skin lesions, as evidenced by a marked decrease in 
skin symptoms and reduced inflammation within the skin 
lesions. Efficacy was confirmed by significant decreases in 
eosinophil ratio and serum IgE concentration, and a reduction 
in the number of Staphylococcus aureus recovered from the 
ear. Moreover, relative mRNA expression levels of IL-4 and 
interferon-γ in the skin lesions of mice injected with IL-10 
plasmid DNA were also decreased compared with those of 
control mice. Of note, higher serum IL-10 levels in mice 
injected with IL-10 plasmid DNA were maintained compared 
with those in control mice. Taken together, the results indicate 
that IL-10 plasmid DNA can suppress the development of 
AD-like skin lesions by suppressing both Th1 and Th2 cell 
responses. Beneficial effects of IL-10 plasmid DNA may be 
expected in dogs with AD.
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Introduction
Canine atopic dermatitis (AD) is one of the most common 
inflammatory skin diseases in small-animal practice [11, 
18]. Severe pruritus and chronic or relapsing eczematous 
skin lesions are major clinical features of this condition [6, 
19]. This condition is most commonly associated with 
immunoglobulin (Ig) E antibodies to environmental allergens 
[24]. Frequent characteristics include elevation of eosinophil 
levels in peripheral blood [9] and increase of staphylococcal 
colonization in mucosal and skin lesions [4]. Although the 
pathogenesis of canine AD is complex, involving genetic, 
environmental and immunological factors, interleukin (IL)-4 
and IL-5 produced by T-helper (Th) 2 cells may have especially 
key roles in its onset and development [23,33]. IL-4 mediates 
an IgE isotype switch in B cells and IL-5 promotes IgE 
synthesis induced by IL-4. Mast cells stimulate the release 
of various chemical mediators in IgE-mediated allergic 
disorders. Subsequently, many types of inflammatory cells 
infiltrate into skin lesions [13]. Although Th2 cells are 
dominant in this acute phase, interferon (IFN)-γ and IL-2 
produced by Th1 cells are highly expressed and contribute 
to the pathogenesis in the chronic phase [16,21]. The above 
knowledge of AD suggests that down-regulation of the 
responses of Th1 and Th2 cells may be effective strategies 
for the management of canine AD.
IL-10, previously known as cytokine synthesis inhibitor 
factor, has potent anti-inflammatory effects mediated by 
the inhibition of IFN-γ and IL-2 produced by Th1 cells [5]. 
It also inhibits IL-4 and IL-5 production by Th2 cells, by 
interfering with B7/CD28-dependent signals [20,30]. 
Moreover, eosinophil survival and IL-4-induced IgE 
synthesis are suppressed by this cytokine [27]. A number 
of studies have reported that IL-10 can ameliorate various 
inflammatory disorders including Crohn’s disease [34], 
psoriasis [1] and hepatic ischemia/reperfusion injury [38].
Despite these interesting therapeutic implications for 
IL-10, the best approaches for delivery of IL-10 in vivo 
remain to be determined. Most studies have been performed 
using systemic delivery of the recombinant IL-10 protein. 
Unfortunately, high dosages of recombinant IL-10 are 
required for maximal therapeutic activity due to the short 
half-life (approximately 20 min in plasma) [3]. Such high 
dosages result in peak plasma IL-10 levels that have 
potentially undesirable systemic effects. To overcome this 
limitation, naked plasmid DNA encoding the IL-10 gene has 
been used in mice; this strategy has produced remarkable 214    Bock-Gie Jung et al.
biological effects with long duration time (approximately 5 
days in plasma) [14]. This long duration time may decrease 
the need for high systemic protein levels associated with 
bolus administration of cytokines, thereby reducing 
undesirable side effects [35].
The present study was performed to examine whether a 
plasmid DNA carrying the IL-10 gene (IL-10 plasmid DNA) 
could suppress development of AD-like skin lesions in NC/ 
Nga mice, a suitable model for AD in human and canines 
[19,32], as an initial step towards the development of an 
appliance for use in dogs with AD.
Materials and Methods
Construction of plasmid DNA encoding IL-10
Total RNA was extracted from mouse spleen using a RNeasy 
Mini Kit (Qiagen, USA) and cDNA was synthesized from 
the extracted RNA using Superscript II reverse transcriptase 
enzyme (Invitrogen, USA) according to the manufacturer’s 
instructions. Mouse IL-10 gene was amplified from the 
synthesized cDNA using polymerase chain reaction (PCR) 
with the following primers: forward primer, 5´-TCC ATC 
ATG CCT GGC TCA-3´ and reverse primer, 5´-GGT GTT 
TTA GCT TTT CAT TTT-3´ (Genebank accession number: 
NM_010548). The underlined nucleotides imply the start and 
stop codon, respectively. The amplified 549 bp PCR products 
were separated by 0.7% (w/v) agarose gel electrophoresis 
and purified using a QIAquick gel extraction kit (Qiagen, 
USA) according to the manufacturer’s instructions. Purified 
mouse IL-10 gene was cloned into pGEM-T Easy vector 
(Promega, USA), and this gene was then sub-cloned into the 
NotI site of the mammalian expression vector pcDNA3.1 
(Invitrogen, USA) to generate pcDNA3.1-IL-10 (named IL-10 
plasmid DNA). The construct was transformed into chemically 
competent Escherichia coli DH5α cells (Invitrogen, USA). 
The transformants were selected on Luria-Bertani media 
(BD Biosciences, USA) supplemented with 100 μg/mL 
ampicillin and the plasmid DNA was extracted using a 
QIAprep Spin Miniprep Kit (Qiagen, USA) according to the 
manufacturer’s instructions. Restriction analysis (NotI) and 
DNA sequencing confirmed the presence and orientation of 
the mouse IL-10 gene in the extracted plasmid DNA. The 
DNA sequencing reactions were performed using an ABI 
PRISM 3100 automated DNA sequencer (Applied Biosystems, 
USA).
Evaluation of mouse IL-10 expression in mammalian 
cells transfected with IL-10 plasmid DNA
To confirm that the constructed IL-10 plasmid DNA was 
functional and to determine the efficiency of protein expression 
in mammalian cells, Vero cells (African green monkey kidney 
cells) were transfected with the IL-10 plasmid DNA using 
the Nanofect transfection reagent (Qiagen, USA) according 
to the manufacturer’s instructions. Briefly, Vero cells were 
maintained in wells of a six-well plate in minimum essential 
medium alpha (α-MEM; Welgene, Korea) supplemented 
with 1% (v/v) antibiotics (Gibco, USA) and 5% (v/v) fetal 
bovine serum (Gibco, USA). When 60-70% confluence was 
reached, the cells were transfected with 2 μg of the IL-10 
plasmid DNA pre-treated with Nanofect transfection reagent 
in α-MEM without serum and antibiotics. Forty-eight hours 
after transfection, the cells were passaged into maintenance 
medium with 2% (v/v) geneticin (Gibco, USA). After colonies 
appeared, surviving cells were selected and passaged into 
fresh maintenance medium. Forty-eight hours after passage, 
the cell culture fluids were collected and analyzed for 
expression of mouse IL-10 protein by the mouse IL-10 
Quantikine ELISA Kit (R&D Systems, USA) according to 
the manufacturer’s instructions. Non-transfected vero cell 
culture fluids were used as negative control, and each sample 
was tested in triplicate.
Animals
Specific pathogen-free (SPF) female 8-week-old NC/Nga 
mice (SLC, Japan) were randomly divided into two groups 
consisting of five mice each. All mice were housed in an 
air-controlled room. Feed and tap water were provided ad 
libitum for all mice. All animal procedures were conducted 
in accordance with the guidelines of the local ethical 
committee (Chonnam National University, Approving number: 
CNU IACUC-YB-2009-15).
Induction of dermatitis and in vivo delivery of the 
IL-10 plasmid DNA in NC/Nga mice
1-chloro-2,4-dinitrobenzene (DNCB; Sigma-Aldrich, 
USA) was used to induce dermatitis in NC/Nga mice 
through repeated cutaneous application as previously 
described [26] with some modification. Briefly, DNCB in 
an acetone/olive oil mixture (3 : 1) was used. Dorsal skin 
regions were shaved with an electric razor on day 0 of 
experiment; this site as well as the glabrous ears were 
sensitized epicutaneously with 200 μL of a 1% (w/v) 
DNCB solution on day 4 of the experiment. Three days 
after sensitization, the dorsal skin and ears were challenged 
with 150 μL of 0.2% (w/v) DNCB solution every 3 days. In 
vivo delivery of the IL-10 plasmid DNA was performed as 
previously described [35]. Briefly, NC/Nga mice were 
intradermally injected with 100 μg of the IL-10 plasmid 
DNA in 100 μL of phosphate-buffered saline (PBS) or PBS 
alone (control) at the base of the tail using a 30-gauge needle 
and a 1 mL syringe on days 1 and 8 of the experiment. 
Peripheral blood and skin samples were collected post 
mortem for analysis 3 days after the third application of 
0.2% (w/v) DNCB solution. The experiment schedule is 
shown in Fig. 1.
Evaluation of clinical skin severity
The severity of dermatitis was evaluated by scoring clinical Interleukin-10 plasmid DNA suppressive effect    215
Fig. 1. Induction of dermatitis and interleukin (IL)-10 plasmid 
DNA injection schedule. Dorsal regions of mice were shaved on 
day 0. The hairless dorsal regions and glabrous ears of mice were 
sensitized with 200 μL of 1% (w/v) DNCB solution on day 4. 
Three days after sensitization, the dorsal skin and ears were 
challenged with 150 μL of 0.2% (w/v) DNCB solution every 3 
days. Following in vivo delivery of IL-10 plasmid DNA, mice 
were intradermally injected with 100 μg of IL-10 plasmid DNA 
in 100 μL of phosphate-buffered saline (PBS) or PBS alone 
(control) on days 1 and 8 of experiment.
signs on the face, ears, nose, neck, and dorsal skin every 3 
days starting from day 4 of the experiment. The total clinical 
skin severity score was defined as the sum of the individual 
scores (none = 0, mild = 1, moderate = 2, and severe = 3). 
Skin severity was characterized according to the presence 
of erythema/hemorrhage, edema, excoriation/erosion, and 
dryness/scaling as previously described [15].
Histological analysis
All mice were sacrificed at the end of the experiment. 
Sampling was performed from dorsal skin lesions and ears, 
and the samples were fixed in 10% phosphate-buffered 
formalin (pH 7.2). Serial paraffin sections 5 μm in thickness 
were cut and stained with hematoxylin and eosin for evaluating 
general skin condition and toluidine blue (pH 4.0) for counting 
mast cells. General skin condition (epidermal hyperplasia, 
hyperkeratosis, and inflammatory cell infiltration and 
dermal infiltration of inflammatory cells) was compared 
between groups as previously described [29]. Mast cell 
number between the epithelium and panniculus carnosus 
was counted under a microscope at a magnification of ×400 
at five sites chosen at random as previously described [12]. 
All histological evaluations were performed in blinded 
fashion.
Measurement  of  eosinophils  ratios  in  peripheral 
leukocytes
Blood was collected in tubes coated with ethylene 
diaminetetraacetic acid. Blood leukocyte and differential 
counts were determined using an automated veterinary 
hematology analyzer (Oxford Science, USA) configured 
for mouse blood.
Enumeration of Staphylococcus (S.) aureus on ear skin
S. aureus was enumerated as previously described [15] 
with some modifications. Briefly, an area of ear skin of about 
1 cm
2 was collected and suspended in 1 mL of sterile PBS. 
One hundred microliters of 10-fold serial dilutions of the 
suspensions were inoculated on mannitol salt medium (BD 
Biosciences, USA) and cultured for 48 h at 37
oC. Yellow 
colonies were counted and expressed as log colony-forming 
units (cfu)/cm
2 (one ear). In addition, representative colonies 
were identified through gram staining and coagulase test [7].
Measurements of IgE and IL-10 concentration in 
serum
Blood was collected from the retro-orbital plexus of each 
mouse at the end of the experiment. Serum was obtained by 
centrifugation and stored at 򰠏20
oC until used. Total serum 
IgE levels were measured using an OptEIA Mouse IgE 
ELISA kit (BD Biosciences, USA) and serum IL-10 levels 
were measured using the Mouse IL-10 Quantikine ELISA 
Kit (R&D Systems, USA) according to the manufacturer’s 
instructions.
Evaluation of relative mRNA expression levels of 
IL-4 and IFN-γ in skin lesions
Skin tissues were collected from dorsal lesions of mice. 
Total RNA extraction was performed using a TRI reagent 
(MRC, USA) and cDNA was synthesized from the extracted 
RNA using Superscript II reverse transcriptase enzyme 
(Invitrogen, USA) according to the manufacturer’s instructions. 
To minimize variations in reverse transcriptase efficiency, 
all samples were transcribed simultaneously. Primers and 
probes for murine IL-4, IFN-γ, and β-actin were designed 
as previously described [25] (Table 1). The probes were dual- 
labelled with the reporter dye 6-carboxyfluorescein (FAM) 
at the 5´ end and the quencher dye 6-carboxytetramethyrhodamine 
(TAMRA) at the 3´ end. IL-4 and IFN-γ mRNA levels were 
determined by real-time PCR using a Rotor-gene 6,000 
(Corbett Research, Australia) with 0.5 μg of cDNA. The 
threshold cycle (Ct; the cycle number at which the amount 
of amplified gene of interest reaches a fixed threshold) was 
determined subsequently. Relative quantitation of IL-4 and 
IFN-γ mRNA expression was calculated by a comparative 
Ct method as previously described [17]. The relative 
quantitation value of target (IL-4 or IFN-γ) was normalized 
to an endogenous control β-actin gene and relative to a 
calibrator. It was expressed as 2
򰠏ΔΔCt (fold), where ΔCt = Ct 
of target gene 򰠏 Ct of endogenous control gene and ΔΔCt = 
ΔCt of samples for target gene 򰠏 ΔCt of the calibrator for the 
target gene.
Statistical analyses
The data were expressed as mean ± SD. A paired Student’s 
t-test was performed for statistical analysis of the data. A 
Mann-Whitney U test (nonparametric test) was used for 
statistical analysis of the clinical skin severity scores. All 
statistical analysis of data performed using SPSS version 
17.0 software (SPSS, USA). p＜0.05 was considered as the 
level of significance.216    Bock-Gie Jung et al.
Fig. 3. The skin features demonstrated visually a marked reduction
in severity of the dermatitis and more rapid hair re-growth with 
IL-10 plasmid DNA injection. (A) Dermatitis induced and PBS 
injected mice, (B) IL-10 plasmid DNA injected mice after 
dermatitis induction.
Table 1. Primer and probe sequences for murine cytokines
Sequence (5´-3´) Length (bp)* Accession
†





IL-4 FW ACAGGAGAAGGGACGCCAT   95 M25892
X05253 RV GAAGCCCTACAGACGAGCTCA
TP TCCTCACAGCAACGAAGAACACCACA
β-actin FW AGAGGGAAATCGTGCGTGAC 148 V01217
J00691 RV CAATAGTGATGACCTGGCCGT
TP CACTGCCGCATCCTCTTCCTCCC
FW: forward primer, RV: reverse primer, TP: TaqMan probe dual-labeled with 5´FAM (report dye) and 3´TAMRA (quencher dye), IFN-γ: 
interferon-gamma, IL-4: interleukin-4. *Amplicon length in base pairs. 
†Genbank accession number of cDNA and corresponding gene.
Fig. 2. Clinical skin severity score in the control mice increased
gradually with the number of cutaneous applications of DNCB and
reached a peak at the end of experiment. A significant improvement
in mice injected with IL-10 plasmid DNA had occurred at day 13
(*p＜0.05) and by day 16 was even more pronounced (**p＜0.01)
compared with the control mice (mean ± SD; n = 5).
Results
Mouse  IL-10  expression  in  mammalian  cells 
transfected with IL-10 plasmid DNA
The sequence of the mouse IL-10 gene in the constructed 
IL-10 plasmid DNA was identical with the original mouse 
IL-10 gene sequence (data not shown). The expression of 
mouse IL-10 in mammalian cells transfected with the 
IL-10 plasmid DNA was confirmed by ELISA. The results 
clearly revealed high expression levels of mouse IL-10 in 
culture fluid of cells transfected with the IL-10 plasmid 
DNA (489.9 ± 9.1 pg/mL). 
    However, the expression levels of mouse IL-10 in 
non-transfected cells was clearly negative (򰠏0.1 ± 0.1 
pg/mL).
Clinical skin severity
Repeated cutaneous application of DNCB accelerates 
development of dermatitis in NC/Nga mice. Consistent with 
this finding, clinical skin severity in the control mice injected 
with PBS alone increased gradually with the number of 
cutaneous applications of DNCB and reached a peak at the 
end of experiment (clinical severity score of 8.6 ± 0.6 points). 
A statistical difference in the clinical skin severity scores was 
observed between mice injected with the IL-10 plasmid 
DNA and control mice after the third application of DNCB 
(Fig. 2). Most control mice exhibited severe symptoms of 
dermatitis including erythema/hemorrhage, edema, excoriation/ 
erosion, and dryness/scaling, while mice injected with the 
IL-10 plasmid DNA presented with mild or moderate 
clinical skin severity (Fig. 3). Interleukin-10 plasmid DNA suppressive effect    217
Fig. 4. Histological features of dorsal skin and dermal mast cell 
infiltration. (A) Hyperplastic epidermis and inflammatory cells 
were notable. (B) The inflammatory infiltrate was less severe in 
mice injected with plasmid DNA. H&E stain, Scale bar = 100 μm.
(C) More severe infiltration of mast cells was evident in control
mice. (D) The mast cell infiltrate was less severe in plasmid DNA 
injected mice. Toluidine blue stain, Scale bar = 50 μm.
Table 2. Epidermal thickness and mast cell number in skin lesions of NC/Nga mice treated with or without IL-10 plasmid DNA
Control IL-10 plasmid DNA
Thickness of epidermis (μm)
† Dorsal lesions 77.64 ± 6.95 51.68 ± 6.37*
Ear lesions 49.16 ± 7.52 29.19 ± 5.76**
Mast cell number (counts/site)
‡ 40.20 ± 3.27 27.6 ± 5.64*
Data are presented as mean ± SD (n = 5). *p＜0.05 vs. control; **p＜0.01 vs. control. 
†Epidermal thickness was measured in five randomly chosen
sites in sections of dorsal and ear skin lesions. 
‡The number of mast cells in five sites chosen randomly at a magnification of ×400 was counted.
Histological analysis
Severe epidermal hyperplasia and hyperkeratosis and 
dense infiltration of inflammatory cells into both the 
epidermis and dermis were observed in both the dorsal and 
ear skin of control mice. However, the IL-10 plasmid DNA 
inhibited these inflammatory changes (Figs. 4A and B). 
Mice injected with the IL-10 plasmid DNA showed a 
significant decrease in the epidermal thickness of dorsal skin 
(p＜0.05) and ear skin (p＜0.01) compared with control 
mice (Table 2). Repeated cutaneous application of DNCB 
increased dermal mast cell number and degranulation in 
control mice. However, these features were significantly 
suppressed by the IL-10 plasmid DNA compared with 
control mice (Figs. 4C and D, Table 2).
Peripheral eosinophil ratio
The ratio of eosinophils in peripheral leukocytes of mice 
injected with the IL-10 plasmid DNA was significantly 
lower than in control mice (p＜0.05) (Fig. 5A).
S. aureus on ear skin
The number of S. aureus (log cfu/cm
2) on the ear in mice 
injected with the IL-10 plasmid DNA showed a significant 
decrease compared with control mice (p＜0.01) (Fig. 5B).
Concentrations of serum IgE and IL-10
The concentration of serum IgE in mice injected with the 
IL-10 plasmid DNA was significantly lower than in control 
mice (p＜0.05) (Fig. 5C). Conversely, the concentration of 
serum IL-10 in mice injected with the IL-10 plasmid DNA 
was significantly higher than in control mice (p＜0.01) 
(Fig. 5D).
Relative mRNA expression level of IL-4 and IFN-γ 
in skin lesions
Relative mRNA expression levels of IL-4 and IFN-γ 
significantly decreased in mice injected with the IL-10 
plasmid DNA compared with those in control mice (p
＜0.05) (Figs. 5E and F).
Discussion
Direct in vivo transfer of naked plasmid DNA was first 
described in 1990 as a novel strategy of gene therapy [37]. 
Initial studies showed muscle to be a suitable target tissue 
for gene delivery [36,37], but skin was also shown to be 
suitable as an alternative site for injection [10,35]. In 
addition, it has been shown that naked plasmid DNA induces 
local or systemic biological effects in vivo, including 
recruitment of neutrophils into the site of IL-8 plasmid DNA 
injection [10] and systemic activation of natural killer cells 
by IL-12 plasmid DNA injection [35]. In the present study, 
to confirm that the constructed IL-10 plasmid DNA was 
functional and to determine the efficiency of protein 
expression in mammalian cells, mouse IL-10 expression 
levels were evaluated in both in vitro culture fluids of cells 
transfected with the IL-10 plasmid DNA and in vivo NC/Nga 
mice injected with the IL-10 plasmid DNA. Mouse IL-10 
levels in culture fluids of transfected cells were much higher 
than those in non-transfected cells. Moreover, serum IL-10 
levels in mice injected with the IL-10 plasmid DNA (51.2 
pg/mL) were maintained over twice that in control mice 
(24.8 pg/mL) at 8 days after two intradermal injections. 218    Bock-Gie Jung et al.
Fig. 5. The inhibitory effects of interleukin-10 plasmid DNA. The 
concentration of serum IL-10 in mice injected with IL-10 plasmid
DNA was significantly higher than in control mice. *p ＜ 0.05 vs.
control, **p ＜ 0.01 vs. control.
These results imply that the IL-10 plasmid DNA is 
functional in mammalian (mouse) cells and has a long 
duration time in mice. These observations are consistent 
with a previous report demonstrating that IL-10 plasmid 
DNA injection induces high and long-lasting levels of serum 
IL-10 in mice [14].
AD-like skin lesions in NC/Nga mice highly resemble 
those of human and canine AD [33] and show various grades 
of clinical features such as erythema and hemorrhage, 
followed by edematous superficial erosion, deep excoriation, 
scaling, and dryness of the skin [15]. However, signs of 
dermatitis vary considerably under conventional conditions 
and clinical skin disorders do not occur in this strain under 
SPF conditions [22]. Therefore, to reduce experimental 
variation and induce stable clinical dermatitis over a short 
period, investigators have adopted the use of hapten-induced 
dermatitis using repeated applications of 1-chloro-2,4,6- 
trinitrobenzene (TNCB); successful development of 
dermatitis in NC/Nga mice under SPF conditions has been 
reported [15,22]. Unfortunately for investigations conducted 
in the Republic of Korea, the importation of TNCB is 
banned. DNCB was used as a rational alternative in view of 
its structural similarity and on the basis of previous evidence 
of its efficacy in creating AD-like skin lesions and IgE 
hyperproduction in NC/Nga mice [26]. In the present study 
the control mice also developed other typical AD signs 
including: erythema, oedema, excoriation, and dryness of 
the skin lesions; hyperplasia and hyperkeratosis of the 
epidermis; dense infiltration of inflammatory cells in the 
dermis; elevation of peripheral blood eosinophil ratio; and 
increased serum IgE concentration. The observation of 
increased colonization of the ear skin by S. aureus in the 
control mice is consistent with the view that massive 
colonization of S. aureus on the skin coincides with the 
severity of dermatitis in NC/Nga mice [12,22].
The present study has demonstrated that IL-10 plasmid 
DNA inhibits development of AD-like skin lesions in 
NC/Nga mice. Macroscopic and microscopic examinations 
revealed markedly decreased clinical skin severity and 
relatively mild epidermal and dermal inflammatory changes 
in mice injected with the IL-10 plasmid DNA compared with 
control mice. Moreover, significant decreases of the 
eosinophil ratio and serum IgE concentration, and a marked 
reduction in the number of S. aureus colonies recovered from 
the ear, confirmed the inhibitory effects of the IL-10 plasmid 
DNA on the development of AD-like skin lesions. Of note, 
relative mRNA expression levels of IL-4 and IFN-γ in the 
skin lesions of mice injected with the IL-10 plasmid DNA 
were decreased compared with those of control mice. These 
results are consistent with previous reports that IL-10 
inhibits IL-4 and IL-5 production by Th2 cells [20,30], and 
IFN-γ and IL-2 production by Th1 cells [5], as well as 
eosinophil survival and IL-4-induced IgE synthesis [27].
Other researchers, on the other hand, found that the 
suppression of IL-10 production by topical application of 
antisense oligonucleotides for IL-10 (AS6) alleviated the 
skin lesions of NC/Nga mice [28]. The discrepancy of the Interleukin-10 plasmid DNA suppressive effect    219
effects of IL-10 on AD could be ascribed to the differences 
in application period (after/before dermatitis-induction), 
application range (local/systemic effects) and target cell 
type [skin-infiltrating T cell / IL-10-producing regulatory T 
cell (Treg)]. As the precise mechanism as to how inhibition 
of IL-10 production by AS6 promotes skin lesion healing has 
yet to be clarified, we hypothesize the following mechanism. 
While IL-10 acts as an immunosuppressive cytokine on 
most cell types, we know that its effect on B cells is to 
enhance viability, proliferation and Ig secretion (the isotype 
switch) [2]. We also know that in dermatitis-induced skin 
lesions, AS6 suppresses IL-10 produced by skin-infiltrating 
T cells. Suppression of IL-10 production by AS6, therefore, 
leads to reduced IgE levels in dermatitis-induced skin 
lesions, with no effect on the IL-4 level [28]. Conversely, the 
present study confirmed that the strong induction of IL-10 
production by systemic application of IL-10 plasmid DNA 
inhibits development of AD-like skin lesions in NC/Nga 
mice. This finding was similar to those of Sawada et al. [29], 
Segawa et al. [31] and Hayashi et al. [8], i.e. the strong 
induction of IL-10 in lymphoid organs and systemic levels 
delays the onset and suppresses the development of AD in 
NC/Nga mice. Sawada et al. [29] pointed out that the 
increased IL-10 level could be due to IL-10-producing Treg 
cells. In the present study, the increased IL-10 level might 
also be due to IL-10-producing Treg cells induced by IL-10 
plasmid DNA. Finally, the mechanism of the beneficial 
effects of the increased IL-10 level might be the strong 
immunosuppressive effects of IL-10 on a systemic level, 
although IL-10 is a pleiotropic cytokine that can exert either 
immunosuppressive or immunostimulatory effects on a 
variety of cell types [2].
Taken together, these findings suggest that intradermal in-
jection of IL-10 plasmid DNA can delay the onset and suppress 
the development of AD-like skin lesions in NC/Nga mice 
by suppressing the response of both Th1 and Th2 cells. Hence, 
IL-10 plasmid DNA may be a good candidate for control of 
AD in dogs. Confirmation of the prophylactic effect of IL-10 
plasmid DNA is now required in dogs with AD.
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